

For Immediate Release
For Further Information Contact:
Therese Fergo at (301) 608-9292
Email: Therese@unither.com

**UNITED THERAPEUTICS' SECOND QUARTER 2001 FINANCIAL RESULTS
DEMONSTRATE CONTINUED GROWTH IN REVENUES AND IMPROVEMENT IN
PER SHARE AMOUNTS**

Silver Spring, MD, August 10, 2001: United Therapeutics Corporation (Nasdaq: UTHR) today announced financial results for the second quarter ended June 30, 2001.

"We are pleased to announce that United Therapeutics ended its second quarter in very strong financial condition. At June 30, 2001, United Therapeutics had \$193.7 million of cash and investments and practically no debt. Revenues during the quarter were \$1.3 million, up 240% from one year ago, and our loss of \$.53 per share is down from \$1.55 in the same quarter of last year," said Fred Hadeed, Chief Financial Officer. Martine Rothblatt, Chairman and CEO, added, "We are very pleased that yesterday the Cardiovascular and Renal Drugs Advisory Committee of the FDA recommended approval of Remodulin for the treatment of pulmonary arterial hypertension by a vote of 6 to 3. Additionally, our second lead drug, Beraprost, is moving quickly through the clinic with approximately 800 patients scheduled to complete the six month final confirmatory pivotal study for peripheral vascular disease this month. We intend to formally present the Beraprost data at the upcoming American Heart Association meeting in November."

Revenues in the second quarter of 2001 were \$1.3 million as compared to revenues of \$546,000 in the previous year. The increase was due primarily from the resales of pumps and supplies to distributors in connection with United Therapeutics' lead product, Remodulin, and sales by subsidiaries acquired late in 2000.

Research and development expenses were \$9.6 million in the second quarter of 2001 as compared to \$28.9 million in the previous year. The decrease was due primarily to the prior year expenditure of approximately \$19.8 million in licensing fees to obtain the exclusive rights to the sustained release formulations of Beraprost. Sales and marketing expenses were \$890,000 in the second quarter of 2001 as compared to none in the previous year. Cost of sales were \$725,000 in the second quarter of 2001 as compared to \$434,000 in the previous year. These increases were due primarily to expanded activities of subsidiaries.

Interest income was \$2.5 million in the second quarter of 2001 as compared to \$1.7 million in the previous year. This increase was attributable to an increase in the amount of cash available for investing resulting from sales of common stock since June 30, 2000, less amounts used for operations.

United Therapeutics is a biotechnology company focused on combating cardiovascular, inflammatory and infectious disease with unique therapeutic products. United Therapeutics is a member of the Russell 3000 Index and is included in the iShares Nasdaq Biotechnology Index Fund (IBB).

UNITED THERAPEUTICS CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS DATA

	<u>Three months ended June 30,</u>		<u>Six months ended June 30,</u>	
	<u>2001</u>	<u>2000</u>	<u>2001</u>	<u>2000</u>
Revenues:				
Sales	\$ 1,134,926	\$ 496,303	\$ 2,397,721	\$ 755,700
Sales to affiliates	135,666	-	355,386	-
Grant revenue	<u>43,361</u>	<u>50,000</u>	<u>43,361</u>	<u>100,000</u>
Total revenues	<u>1,313,953</u>	<u>546,303</u>	<u>2,796,468</u>	<u>855,700</u>
Operating expenses:				
Research and development	9,597,049	28,935,915	18,065,902	34,712,664
General and administrative	3,075,561	1,696,384	6,995,560	5,497,534
Sales and marketing	889,778	-	1,733,889	-
Cost of sales	<u>724,711</u>	<u>433,587</u>	<u>1,529,994</u>	<u>653,870</u>
Total operating expenses	<u>14,287,099</u>	<u>31,065,886</u>	<u>28,325,345</u>	<u>40,864,068</u>
Loss from operations	(12,973,146)	(30,519,583)	(25,528,877)	(40,008,368)
Other income (expense):				
Interest income	2,453,681	1,712,868	5,738,208	3,270,726
Interest expense	(54,245)	(27,664)	(93,423)	(55,660)
Equity in loss of affiliate	(93,082)	-	(154,614)	-
Other – net	<u>19,855</u>	<u>24,063</u>	<u>(11,015)</u>	<u>71,389</u>
Total other income	<u>2,326,209</u>	<u>1,709,267</u>	<u>5,479,156</u>	<u>3,286,455</u>
Net loss before income tax	(10,646,937)	(28,810,316)	(20,049,721)	(36,721,913)
Income tax	-	-	-	-
Net loss	<u>\$ (10,646,937)</u>	<u>\$ (28,810,316)</u>	<u>\$ (20,049,721)</u>	<u>\$ (36,721,913)</u>
Net loss per common share - basic and diluted	<u>\$ (0.53)</u>	<u>\$ (1.55)</u>	<u>\$ (0.99)</u>	<u>\$ (2.01)</u>
Weighted average number of common shares outstanding - basic and diluted	<u>20,277,089</u>	<u>18,585,976</u>	<u>20,334,566</u>	<u>18,305,618</u>

CONSOLIDATED BALANCE SHEET DATA

	<u>June 30,</u>	<u>December 31,</u>
	<u>2001</u>	<u>2000</u>
Cash, Cash Equivalents, Marketable Investments, and Certificate of Deposit	\$193,745,017	\$215,990,326
Total Assets	\$229,840,557	\$250,644,984
Total Stockholders' Equity	\$213,594,636	\$234,737,782